Differential Expression Levels of Plasma microRNAs in Neuroblastoma Patients Identified by Next-Generation Sequencing
Hiroshima Journal of Medical Sciences 69 巻 2 号
39-45 頁
2020-06-30 発行
アクセス数 : 637 件
ダウンロード数 : 116 件
今月のアクセス数 : 5 件
今月のダウンロード数 : 0 件
この文献の参照には次のURLをご利用ください : https://ir.lib.hiroshima-u.ac.jp/00049780
| ファイル情報(添付) | |
| タイトル ( eng ) |
Differential Expression Levels of Plasma microRNAs in Neuroblastoma Patients Identified by Next-Generation Sequencing
|
| 作成者 |
ARFAN Ahmad
KOJIMA Masato
KIMURA Shingo
|
| 収録物名 |
Hiroshima Journal of Medical Sciences
|
| 巻 | 69 |
| 号 | 2 |
| 開始ページ | 39 |
| 終了ページ | 45 |
| 収録物識別子 |
[PISSN] 0018-2052
[EISSN] 2433-7668
[NCID] AA00664312
|
| 抄録 |
Efforts to identify biomarkers for neuroblastoma (NB) have been ongoing, but no definite biomarker has been identified in peripheral blood. We proposed the use of plasma exosomal miRNAs as biomarkers of unfavorable NB patient outcomes. Exosomal miRNAs isolated from 31 plasma and 37 tissue samples, many from the same NB patients, were sequenced using a next-generation sequencing instrument. We analyzed the correlation between miRNA expression levels in plasma and tissue samples with International Neuroblastoma Risk Group staging system (INRGSS) outcome and MYCN status. We chose differentially expressed miRNAs with similar expression patterns in plasma and tissue samples in each of the three analysis groups and combined those miRNAs to find the optimal combination with the potential to be considered as a biomarker. MicroRNA-92a-3p was found to be significantly upregulated in deceased patients (p = 0.017), miR-375 was upregulated in INRGSS stage M patients (p = 0.002), and plasma miR-92a-3p and miR-99a-5 levels were upregulated in patients with MYCN amplification (p = 0.007 and 0.006). The combination of miR-92a-3p, miR-375, and miR-99a-5p levels was shown to be a statistically significant predictor of NB patient outcomes (AUC = 0.726, p = 0.001, 95% CI = 0.612–0.841, sensitivity = 77%, specificity = 56.7%). Thus, the combination of miR-92a3p, miR-375, and miR-99a-5p may potentially be used as a biomarker for unfavorable NB patient outcomes. However, further validation is required in a larger number of NB patients.
|
| 著者キーワード |
Neuroblastoma
microRNA
Prognosis
NGS
|
| 内容記述 |
This research was partially supported by a Grant-in-Aid for Scientific Research (A) (No.19H0105600) from the Ministry of Education, Culture, Sports, Science and Technology.
|
| 言語 |
英語
|
| 資源タイプ | 紀要論文 |
| 出版者 |
Hiroshima University Medical Press
|
| 発行日 | 2020-06-30 |
| 権利情報 |
Copyright (c) 2020 Hiroshima University Medical Press
|
| 出版タイプ | Version of Record（出版社版。早期公開を含む） |
| アクセス権 | オープンアクセス |
| 収録物識別子 |
[ISSN] 0018-2052
[ISSN] 2433-7668
[NCID] AA00664312
[DOI] 10.24811/hjms.69.2_39
[DOI] https://doi.org/10.24811/hjms.69.2_39
|
